QPPV.COM KNOWLEDGE ASSESSMENT

Product Quality Complaints and Pharmacovigilance: Where the Systems Meet

Test your understanding of the concepts covered by Product Quality Complaints and Pharmacovigilance: Where the Systems Meet.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best describes the relationship between ICSR submission and quality-defect notification?
Question 2 of 10 A patient reports a damaged carton received in transit, with no use of the medicine and no health event. What is the best interpretation?
Question 3 of 10 An MAH uses a contractor to receive patient calls and route complaints. Which control is most important for reconstructing PV awareness and assessing the interface?
Question 4 of 10 How should a company handle the awareness clocks when the same contact raises both a possible adverse reaction and a suspected quality defect?
Question 5 of 10 A product complaint later yields information identifying a patient and a suspected adverse reaction. What should the organisation do?
Question 6 of 10 Which statement best describes the appropriate basis for seriousness classification of an ICSR associated with a suspected defect?
Question 7 of 10 A company observes an increase in complaints about device breakage, but the number of exposed patients and reporting propensity are unknown. What can reasonably be concluded?
Question 8 of 10 Which statement best describes information access between PV and Quality when linked records contain patient information?
Question 9 of 10 A MAH delegates intake and case-processing tasks to partners. Which governance principle remains important?
Question 10 of 10 A patient reports that a prefilled syringe leaked and that they developed a rash after using it. The batch investigation has not yet begun. What is the most appropriate initial approach?

Select an answer to continue.

QPPV.com